1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsExtramural Medical Countermeasures (MCM) Regulatory Science Research is sponsored by U.S. Food and Drug Administration (FDA) Office of Regulatory and Emerging Science (ORES). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Extramural MCM Regulatory Science Research | FDA Skip to in this section menu Emergency Preparedness and Response Public Health Preparedness and Response Medical Countermeasures (MCMs) Extramural MCM Regulatory Science Research The Office of Regulatory and Emerging Science (ORES) provides funding to support high-priority regulatory science research for internal FDA scientists as well as for external scientists that align with U.S. Government medical countermeasure (MCM) priorities to develop the tools, standards, and approaches necessary to assess MCM safety, efficacy, quality, and performance.
Our work helps translate cutting-edge science and technology into safe and effective MCMs needed to respond to chemical, biological, radiological, and nuclear threats (CBRN) threats and emerging infectious diseases.
ORES funds extramural MCM regulatory science using various contract and grant mechanisms including the FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science (under research area of interest III).
Developing and cauterizing tools to support MCM development under the Animal Rule , or Emergency Use Authorization ( EUA ) Enhancing the agility, quality, and utility of diagnostics and diagnostic data Modernizing tools to evaluate MCM product safety, efficacy, and quality; and secure the MCM supply chain Advancing the development of tools to enable the rapid development and availability of investigational MCMs Characterizing immunity to Ebola and Marburg to support medical countermeasure development University of California, Los Angeles (UCLA) School of Public Health September 2019 - March 2025 FDA and global partners to analyze coronavirus samples Study expanded to add characterization of SARS-CoV-2 (including variants of concern) pathogenesis and disease severity in humans and animal models (August 2021) September 2020 - September 2025 Cellular signaling and immune correlates for SARS-CoV-2 infection Study expanded to research diversity of immune responses across clinical populations (September 2021) Stanford University School of Medicine October 2020 - September 2025 Expanding next-generation sequencing tools to support pandemic preparedness and response Embleema and George Washington University September 2021 - September 2025 Strengthening coronavirus models with systems biology and machine learning Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australia September 2021 – September 2026 Pediatric disease modeling for long COVID Children’s Hospital Los Angeles Development of a Novel Challenge Model of Systemic Botulinum Neurotoxin Intoxication to Support the Advancement of Candidate Therapeutic Medical Countermeasures Battelle Memorial Institute Development of an Alternative Ferret Nerve Agent Exposure Model for Chemical Agent Countermeasure Evaluation Battelle Memorial Institute Adverse Events Monitoring and Analysis Pilot Program September 2013 - March 2015 Cross-Species Immune System Reference Ensuring Appropriate Public Use of Medical Countermeasures through Effective Emergency Communication University of Pittsburgh Medical Center - UPMC Center for Health Security Investigating Decontamination and Reuse of Respirators in Public Health Emergencies Battelle Memorial Institute Companion Studies to Define the Distribution and Duration of Zika Virus in Non-Human Primates University of California, Davis Supporting Field Laboratory Testing of Ebola Antibodies in Sierra Leone National Institute for Infectious Diseases “Lazzaro Spallanzani” (INMI) September 2015 - September 2018 Organs-On-Chips for Radiation Countermeasures Study expanded to analyze differences in sex-specific responses to radiation in September 2018 Wyss Institute for Biologically Inspired Engineering at Harvard University Streamlining Countermeasure Data Collection During Public Health Emergencies (Discovery, the Critical Care Research Network) University of Southern California September 2014 - September 2019 Optimizing Respirator Decontamination to Ensure Supplies for Emergency Preparedness Applied Research Associates, Inc. (ARA) September 2014 - September 2019 Melioidosis Modeling: Research to Support Countermeasures for a Tricky Pathogen Defence Science and Technology Laboratory (Dstl) September 2015 - September 2019 Developing a Toolkit to Assess Efficacy of Ebola Vaccines and Therapeutics Study expanded to apply technology used for the Ebola project to gather important information about COVID-19 infection (March 2020) Public Health England (PHE) September 2015 - March 2021 Assessing the Role of Additive Manufacturing in Support of the U.S. COVID-19 Response National Center for Defense Manufacturing and Machining (America Makes) September 2020 - February 2021 U.S. Department of Defense and FDA collaborate to help speed potential countermeasures for Ebola and other viruses U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) September 2018 - September 2021 A new approach for understanding Ebola virus pathogenesis Study expanded to apply technology used for the Ebola project to gather important information about COVID-19 infection (March 2021) Broad Institute of MIT and Harvard November 2018 - September 2021 Survivor Studies: Better Understanding Ebola's After-Effects to Help Find New Treatments Study expanded to include investigation of Zika virus disease (September 2017), apply new technologies (September 2019), and development and evaluation of potential medical countermeasures for COVID-19 (March 2020) Stanford University School of Medicine Comparison of Host Responses to Ebola Virus Disease (EVD) Study expanded to apply technology used for the Ebola project to gather important information about COVID-19 infection (March 2020) UK Health Security Agency (formerly Public Health England) Human organ chips for radiation countermeasure development Study expanded to add development of new organs-on-chips to aid development and evaluation of countermeasures for COVID-19 (September 2021) Wyss Institute for Biologically Inspired Engineering at Harvard University September 2019 - March 2024 Provision of Marburg Virus Control Serum Using real-world evidence to advance COVID-19 medical countermeasures View FDA BAA awards in other research areas Focus Areas of Regulatory Science (FARS) report Public Health Emergency Medical Countermeasures Enterprise priorities
According to the current listing, eligibility includes: External scientists at universities and other research organizations are eligible. Confirm the full requirements in the official notice before applying.
Extramural Medical Countermeasures (MCM) Regulatory Science Research is funded by U.S. Food and Drug Administration (FDA) Office of Regulatory and Emerging Science (ORES). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The Hewlett Foundation's Emerging Technology and Security Initiative commits $20 million a year through 2031 across AI, biotechnology, and quantum computing security. Its 2026 exploratory grants went to thirteen named institutions with no open call. For organizations outside that list, the path in runs through a specific set of moves — and the five-year term starting in 2027 is the window.
Read articleThe AFID Infrastructure Grant program closes October 30, 2026. Awards top out at $50,000, they are reimbursable, and only a political subdivision can apply. The August round put $507,000 into 14 projects at an average of about $36,000.
Read articleThe Emerging Health Innovators solicitation drops on SAM.gov by the end of September 2026 with 16 named topic areas, an eight-year terminal-degree ceiling, and an eligibility screen that bars national labs, FFRDCs, UARCs, and anyone who has ever led an ARPA prime award. Proposers' Day is October 13. Here is how to read the design.
Read article